Literature DB >> 12150818

A genome-based strategy uncovers frequent BRAF mutations in melanoma.

Pamela M Pollock1, Paul S Meltzer.   

Abstract

Using a genome-scanning approach to search for oncogenes, a recent report identifies somatic mutations in the signaling gene BRAF that are particularly prevalent in melanoma.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12150818     DOI： 10.1016/s1535-6108(02)00089-2

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  40 in total

1.  Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.

Authors:  Tri K Nguyen; Nicholas Jordan; Jonathan Friedberg; Richard I Fisher; Paul Dent; Steven Grant
Journal:  Leuk Res       Date:  2010-02-01       Impact factor: 3.156

Review 2.  Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

Authors:  Jun Guo; Shukui Qin; Jun Liang; Tongyu Lin; Lu Si; Xiaohong Chen; Zhihong Chi; Chuanliang Cui; Nan Du; Yun Fan; Kangsheng Gu; Fang Li; Junling Li; Yongheng Li; Houjie Liang; Jiwei Liu; Man Lu; Aiping Lu; Kejun Nan; Xiaohui Niu; Hongming Pan; Guoxin Ren; Xiubao Ren; Yongqian Shu; Xin Song; Min Tao; Baocheng Wang; Wenbin Wei; Di Wu; Lingying Wu; Aiwen Wu; Xiaolin Xu; Junyi Zhang; Xiaoshi Zhang; Yiping Zhang; Huiyan Zhu
Journal:  Ann Transl Med       Date:  2015-12

Review 3.  Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

Authors:  Darshil J Shah; Roxana S Dronca
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

4.  Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.

Authors:  Sulochana S Bhandarkar; Jacqueline Bromberg; Carol Carrillo; Ponniah Selvakumar; Rajendra K Sharma; Betsy N Perry; Baskaran Govindarajan; Levi Fried; Allie Sohn; Kalpana Reddy; Jack L Arbiser
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

Review 5.  BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.

Authors:  Pedro Madureira; Ramon Andrade de Mello
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

Review 6.  Controversial aspects of oncogene-induced senescence.

Authors:  Anna Bianchi-Smiraglia; Mikhail A Nikiforov
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

Review 7.  Vemurafenib: the first drug approved for BRAF-mutant cancer.

Authors:  Gideon Bollag; James Tsai; Jiazhong Zhang; Chao Zhang; Prabha Ibrahim; Keith Nolop; Peter Hirth
Journal:  Nat Rev Drug Discov       Date:  2012-10-12       Impact factor: 84.694

8.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

9.  Global comparative gene expression analysis of melanoma patient samples, derived cell lines and corresponding tumor xenografts.

Authors:  Yaguang Xi; Adam Riker; Lalita Shevde-Samant; Rajeev Samant; Christopher Morris; Elaine Gavin; Oystein Fodstad; Jingfang Ju
Journal:  Cancer Genomics Proteomics       Date:  2008 Jan-Feb       Impact factor: 4.069

10.  Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.

Authors:  S C Edmunds; I A Cree; F Dí Nícolantonío; J L Hungerford; J S Hurren; D P Kelsell
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.